Holzer & Holzer, LLC is investigating Capricor Therapeutics for possible violations of federal securities laws after the FDA reported that Capricor's stem cell treatment for Duchenne muscular dystrophy did not meet Phase 3 trial objectives, contradicting the company's earlier claims. This news caused Capricor's stock price to drop. Investors who suffered losses are encouraged to contact the law firm to discuss potential legal actions. The investigation highlights concerns about the accuracy of Capricor's public statements and the impact on shareholders.
Resideo's Senior Vice President, Mehta, recently purchased 10,928 shares of the company's stock through a direct purchase valued at $226,000. This insider buying can signal confidence in the company's future prospects and may influence investor senti...
Arthur Hayes, co-founder of BitMEX, purchased 244,406 UNI tokens worth $1.73 million through an OTC deal with Flowdesk, avoiding market impact. This sizable buy is notable as there is no current governance proposal or upgrade driving the purchase, in...
Greg Abel, Warren Buffett's successor, invested heavily in a single stock, spending $4.5 billion last quarter and at least $3.3 billion this quarter. This large purchase indicates strong confidence in the stock's future prospects. Investors may view ...
Shiba Inu's futures market has seen a 19.28% surge in open interest, with over 10.74 trillion SHIB tokens committed to derivatives trading. This surge follows a nearly 5% price increase, helping SHIB maintain its key $0.000005 level despite recent co...
EURR, a new euro-backed stablecoin launched by Bridge Building S.A., gained $665,300 in market cap within 24 hours shortly after its August 26, 2026 launch. Backed 1:1 by euros held in regulated banks and compliant with the EU's MiCA regulations, EUR...
